CLINICAL_TRIALS
trial_result
· 2026-02-27
Clinical Trial Update: Open-Label Extension of EryDex Study IEDAT-04-2022 [Phase 3]
Summary
A Phase 3 open-label extension of EryDex for Ataxia Telangiectasia has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Quince Therapeutics S.p.A. | Conditions: Ataxia Telangiectasia | Phase 3 | Status: TERMINATED